Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Mauna Kea Technologies
  6. News
  7. Summary
    MKEA   FR0010609263

MAUNA KEA TECHNOLOGIES

(MKEA)
  Report
Real-time Euronext Paris  -  11:35 2022-11-28 am EST
0.4635 EUR   -1.59%
11/17Mauna Kea Technologies reports its Financial Results for the First Half of 2022
AQ
11/07Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China
CI
11/01Mauna Kea Technologies Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease and its Publication in Gastroenterology
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements

07/11/2022 | 11:45am EST

Mauna Kea Technologies and Tasly Pharmaceuticals announced the execution of an agreement to form a Joint Venture (JV). Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufacture Cellvizio units for the Chinese market. The JV will utilize both existing distribution partners and its own network of China-based marketing professionals to accelerate market adoption.

In exchange for contributing licenses and other intellectual property to the JV, Mauna Kea will receive cash payments totaling $10 million, a 44.1% equity interest in the JV, and a 5-year commitment to purchase minimum quantities of Cellvizio systems and probes. Mauna Kea's equity holdings are net of shares issued to Cenponts Tech Limited in consideration for strategic advisory services provided in connection to the transaction. The Joint Venture will be majority owned and funded by Tasly and jointly managed by Tasly and Mauna Kea.

The Joint Venture will be in an immediate position to leverage Mauna Kea's position as global leader in probe and needle-based confocal laser endomicroscopy, with its FDA clearance for neurosurgery applications, its broad regulatory clearances in the Chinese market as well as its significant installed based in leading hospitals in China.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
MAUNA KEA TECHNOLOGIES -1.59% 0.4635 Real-time Quote.-39.41%
TASLY PHARMACEUTICAL GROUP CO., LTD 0.26% 11.74 End-of-day quote.-25.93%
All news about MAUNA KEA TECHNOLOGIES
11/17Mauna Kea Technologies reports its Financial Results for the First Half of 2022
AQ
11/07Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Ve..
CI
11/01Mauna Kea Technologies Announces Success of Clinical Trial on Prediction of Remission i..
AQ
10/31Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remissio..
CI
10/27Mauna Kea Technologies SA Reports Sales Results for the Third Quarter and Nine Months o..
CI
10/27Mauna Kea Technologies : Announces 2022 Nine Month Sales Results
PU
10/05Mauna Kea Technologies Chairman Assumes CEO Role
MT
10/04Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive..
CI
10/04MAUNA KEA TECHNOLOGIES : Changes in management and corporate offi..
CO
09/20Mauna Kea Technologies Postpones Release of its 2022 Half-Year Financial Results
CI
More news
Financials
Sales 2022 10,4 M 10,8 M 10,8 M
Net income 2022 -10,1 M -10,5 M -10,5 M
Net Debt 2022 30,3 M 31,5 M 31,5 M
P/E ratio 2022 -1,93x
Yield 2022 -
Capitalization 20,6 M 21,4 M 21,4 M
EV / Sales 2022 4,89x
EV / Sales 2023 4,32x
Nbr of Employees 87
Free-Float 74,4%
Chart MAUNA KEA TECHNOLOGIES
Duration : Period :
Mauna Kea Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAUNA KEA TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,46 €
Average target price 2,45 €
Spread / Average Target 429%
EPS Revisions
Managers and Directors
Sacha Loiseau Chairman & Chief Executive Officer
Shui Gautheron Chief Financial Officer
François Lacombe Chief Scientific Officer
Aline Criton Chief Clinical & Regulatory Affairs Officer
Frédéric Banégas Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
MAUNA KEA TECHNOLOGIES-39.41%21
SARTORIUS AG-38.27%24 824
QUIDELORTHO CORPORATION-37.14%5 825
BIOTAGE AB (PUBL)-29.50%1 169
REVENIO GROUP OYJ-25.33%1 146
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.53.30%1 089